haha, gold.
"More funding could be required if Teva partnership ceases: Partner Teva is currently funding
phase 3 heart failure study through to an interim analysis of the data for the first ~120 patients. Its
contractual obligation does not extend beyond this point however, meaning that it may decide not
to fund the project further, depending on the outcome of the data. If this occurs, and MSB chooses
to continue with the study under its own funding, cash burn would rise."
This interim analysis was due 1Q16 - is it still going to happen? Who is funding this trial from here?
Ann: Phase 3 Heart Failure Trial Size Substantially Reduced, page-17
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |